Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FORUM MARKETS IncATNF · Entity 7020 | COO / Chief Business Officer | December 16, 2021 | December 16, 2021 |
| Monopar TherapeuticsMNPR · Entity 5152 | Chief Financial Officer | September 30, 2026 | October 02, 2026 |
| Ocugen, Inc.OCGN · Entity 5550 | CFO/CBO | March 06, 2023 | March 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FORUM MARKETS Inc
Report date December 16, 2021 · Filed December 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,500 |
Reported balance
After 2021-12-16 transaction · row 1
1 source rowRow 1 · 2021-12-16 · Purchase · Acquired 8,000 · Balance 20,500 |
Monopar Therapeutics
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,655 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 614 · Balance 2,835 F1: Represents shares acquired on vesting and settlement of restricted stock units. Row 2 · 2026-09-30 · Tax withholding · Disposed 180 · Balance 2,655 F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 7,984 |
Reported balance
After 2026-09-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-30 · Exercise / conversion · Disposed 614 · Balance 7,984 F1: Represents shares acquired on vesting and settlement of restricted stock units. F3: On December 2, 2025, the reporting person was granted 9,826 restricted stock units, vesting 6/48ths (1,228) on June 30, 2026, and 3/48ths (614 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired on vesting and settlement of restricted stock units.
F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3: On December 2, 2025, the reporting person was granted 9,826 restricted stock units, vesting 6/48ths (1,228) on June 30, 2026, and 3/48ths (614 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
Ocugen, Inc.
Report date March 06, 2023 · Filed March 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 165,934 |
Reported balance
Holding disclosure · report date 2023-03-06 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 165,934 F1: Includes 163,934 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of Ocugen, Inc. (the "Company"). The RSUs vest annually in equal installments over three years commencing on February 16, 2024, in each case subject to continued service with the Company on the applicable vesting dates. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2033-02-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-03-06 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The option vests annually in equal installments over three years commencing on February 16, 2024, subject to continued service with the Company on the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 163,934 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of Ocugen, Inc. (the "Company"). The RSUs vest annually in equal installments over three years commencing on February 16, 2024, in each case subject to continued service with the Company on the applicable vesting dates. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.
F2: The option vests annually in equal installments over three years commencing on February 16, 2024, subject to continued service with the Company on the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 22:14 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Unit · Derivative | 614 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-031924 · rdgdoc.xml · derivative · entry 3 Vu Quan Anh · CIK 0001892297 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,984 Underlying: Common Stock · 614 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On December 2, 2025, the reporting person was granted 9,826 restricted stock units, vesting 6/48ths (1,228) on June 30, 2026, and 3/48ths (614 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On December 2, 2025, the reporting person was granted 9,826 restricted stock units, vesting 6/48ths (1,228) on June 30, 2026, and 3/48ths (614 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 22:14 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 180 | $79.67 | $14,340.60 |
DisclosureSEC source: 0001437749-26-031924 · rdgdoc.xml · nonDerivative · entry 2 Vu Quan Anh · CIK 0001892297 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,655 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 22:14 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 614 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-031924 · rdgdoc.xml · nonDerivative · entry 1 Vu Quan Anh · CIK 0001892297 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Unit · Derivative | 1,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-022631 · rdgdoc.xml · derivative · entry 3 Vu Quan Anh · CIK 0001892297 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,598 Underlying: Common Stock · 1,228 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On December 2, 2025, the reporting person was granted 9,826 restricted stock units, vesting 6/48ths (1,228) on June 30, 2026, and 3/48ths (614 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On December 2, 2025, the reporting person was granted 9,826 restricted stock units, vesting 6/48ths (1,228) on June 30, 2026, and 3/48ths (614 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 507 | $92.59 | $46,943.13 |
DisclosureSEC source: 0001437749-26-022631 · rdgdoc.xml · nonDerivative · entry 2 Vu Quan Anh · CIK 0001892297 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,221 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,228 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-022631 · rdgdoc.xml · nonDerivative · entry 1 Vu Quan Anh · CIK 0001892297 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 17:15 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 1,500 | $69.95 | $104,925.00 |
DisclosureSEC source: 0001437749-25-038804 · rdgdoc.xml · nonDerivative · entry 1 Vu Quan Anh · CIK 0001892297 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Read SEC document |
| December 02, 2025 Filed Dec 8, 2025 21:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 9,826 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-037164 · rdgdoc.xml · derivative · entry 2 Vu Quan Anh · CIK 0001892297 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,826 Underlying: Common Stock · 9,826 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter. F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter. Read SEC document |
| December 02, 2025 Filed Dec 8, 2025 21:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 7,135 | $0.00 Strike: $75.94 | $0.00 |
DisclosureSEC source: 0001437749-25-037164 · rdgdoc.xml · derivative · entry 1 Vu Quan Anh · CIK 0001892297 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,135 Underlying: Common Stock · 7,135 shares Expires 2035-12-02 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2026, and 1/48th per month thereafter. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:06 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $30.93 | $0.00 |
DisclosureSEC source: 0001437749-25-006297 · rdgdoc.xml · derivative · entry 1 Vu Quan Anh · CIK 0001892297 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-03-02 F1 · derivative.exercise_date: On March 3, 2025, the reporting person was granted 25,000 stock options, vesting 6/48ths (15,625 shares) on September 2, 2025, and 1/48th every month thereafter until the stock option is fully vested on March 3, 2029. Read SEC document |
| December 16, 2021 Filed Dec 16, 2021 22:00 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | PurchaseCommon Stock | 8,000 | $3.98 | $31,840.00 |
DisclosureSEC source: 0001213900-21-065725 · ownership.xml · nonDerivative · entry 1 Vu Quan Anh · CIK 0001892297 · COO / Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 23:04 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | PurchaseCommon Stock | 4,500 | $3.90 | $17,550.00 |
DisclosureSEC source: 0001213900-21-064763 · ownership.xml · nonDerivative · entry 1 Vu Quan Anh · CIK 0001892297 · COO / Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 13:20 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001213900-21-064568 · ownership.xml · derivative · entry 2 Vu Quan Anh · CIK 0001892297 · COO / Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-12-08 F1 · kind: The Stock Options were granted to the Reporting Person pursuant to the Issuer's 2020 Omnibus Incentive Plan in consideration for services to be rendered as COO / Chief Business Officer. Exempt from Section 16(b) of the Securities Exchange Act of 1934 under Rule 16b-3. F2 · derivative.exercise_date: The options vest in 48 equal monthly installments, beginning on the last day of November 2021, and continuing on the last day of each calendar month thereafter, subject to the Reporting Person's continued service to the Company on such vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.